Immunotherapy

The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.

H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

The partners will develop technology to predict the outcome of an NK-cell-based immunotherapy in patients with incurable locally advanced or metastatic solid tumors.

Researchers were able to identify 40 tumor-specific antigens within two mouse cancer cell lines and seven human primary tumors using this approach.

Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.

During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.